在 COVID-19 大流行期间，为 SCA 患儿启动预防中风的辅助低剂量羟基脲治疗。

Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.

出版信息

Blood. 2020 May 28;135(22):1997-1999. doi: 10.1182/blood.2020005992.

DOI:10.1182/blood.2020005992

PMID:32282033

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7256359/

Abstract

There is a Commentary on this article in this issue.

摘要

本期对这篇文章有评论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ded7/7256359/b4fb7b03e602/bloodBLD2020005992f1.jpg

相似文献

Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.

Blood. 2020 May 28;135(22):1997-1999. doi: 10.1182/blood.2020005992.

Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.

Blood. 2020 Jun 18;135(25):2320-2322. doi: 10.1182/blood.2020006582.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

Expanding the role of hydroxyurea in children with sickle cell disease.

J Pediatr. 2004 Sep;145(3):287-8. doi: 10.1016/j.jpeds.2004.06.032.

Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.

J Pediatr. 2005 Oct;147(4):560-1. doi: 10.1016/j.jpeds.2005.03.045.

Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.

Am J Hematol. 2011 Apr;86(4):357-61. doi: 10.1002/ajh.21986.

Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.

Am J Hematol. 2019 Nov;94(11):E305-E307. doi: 10.1002/ajh.25616. Epub 2019 Sep 11.

Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.

J Pediatr. 2004 Sep;145(3):346-52. doi: 10.1016/j.jpeds.2004.04.058.

Prospects for primary stroke prevention in children with sickle cell anaemia.

Br J Haematol. 2012 Apr;157(1):14-25. doi: 10.1111/j.1365-2141.2011.09005.x. Epub 2012 Jan 9.

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Blood. 2012 Apr 26;119(17):3925-32. doi: 10.1182/blood-2011-11-392340. Epub 2012 Feb 7.

引用本文的文献

Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease.

J Am Heart Assoc. 2024 Jun 18;13(12):e033278. doi: 10.1161/JAHA.123.033278. Epub 2024 Jun 6.

Covid-19 impacts: Ethnic and regional inequalities in sickle cell disease patient care in Brazil.

Heliyon. 2023 Nov 11;9(11):e21960. doi: 10.1016/j.heliyon.2023.e21960. eCollection 2023 Nov.

Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators.

Br J Haematol. 2023 Dec;203(5):712-721. doi: 10.1111/bjh.19099. Epub 2023 Sep 10.

Blood Transfusion Vs. Hydroxyurea for Stroke Prevention in Children With Sickle Cell Anemia: A Systematic Review and Meta-Analysis.

Cureus. 2022 Nov 22;14(11):e31778. doi: 10.7759/cureus.31778. eCollection 2022 Nov.

Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.

Blood. 2022 May 19;139(20):3030-3039. doi: 10.1182/blood.2021013873.

Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.

Int J Mol Sci. 2021 Nov 8;22(21):12081. doi: 10.3390/ijms222112081.

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.

Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.

Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy).

Indian Dermatol Online J. 2021 Jan 16;12(1):58-65. doi: 10.4103/idoj.IDOJ_685_20. eCollection 2021 Jan-Feb.

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Orphanet J Rare Dis. 2021 Mar 1;16(1):114. doi: 10.1186/s13023-021-01757-w.

COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications.

Ann Hematol. 2021 May;100(5):1115-1122. doi: 10.1007/s00277-021-04441-y. Epub 2021 Feb 1.

本文引用的文献

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Am J Hematol. 2019 Apr;94(4):E112-E115. doi: 10.1002/ajh.25412. Epub 2019 Feb 6.

Beneficial Effect of Low Fixed Dose of Hydroxyurea in Vaso-occlusive Crisis and Transfusion Requirements in Adult HbSS Patients: A Prospective Study in a Tertiary Care Center.

Indian J Hematol Blood Transfus. 2018 Apr;34(2):294-298. doi: 10.1007/s12288-017-0869-x. Epub 2017 Sep 4.

Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).

Am J Hematol. 2018 Mar;93(3):E83. doi: 10.1002/ajh.25012. Epub 2018 Feb 2.

Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26401. Epub 2016 Dec 30.

Central nervous system complications and management in sickle cell disease.

Blood. 2016 Feb 18;127(7):829-38. doi: 10.1182/blood-2015-09-618579. Epub 2016 Jan 12.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Lancet. 2016 Feb 13;387(10019):661-670. doi: 10.1016/S0140-6736(15)01041-7. Epub 2015 Dec 6.

How I treat and manage strokes in sickle cell disease.

Blood. 2015 May 28;125(22):3401-10. doi: 10.1182/blood-2014-09-551564. Epub 2015 Mar 30.

Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.

Niger Postgrad Med J. 2013 Sep;20(3):181-7.

Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.

Am J Hematol. 2011 Oct;86(10):846-50. doi: 10.1002/ajh.22142. Epub 2011 Sep 2.

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

N Engl J Med. 1998 Jul 2;339(1):5-11. doi: 10.1056/NEJM199807023390102.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

在 COVID-19 大流行期间，为 SCA 患儿启动预防中风的辅助低剂量羟基脲治疗。

Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献